BioNTech reported second-quarter revenue of EUR 106 million, or a 59% year-on-year decline. Management lowered its guidance for full-year revenue to EUR 1.6 billion-EUR 1.9 billion, or 19% lower than previous guidance at the midpoint, citing lower covid vaccine demand and delayed milestone payments.
BioNTech owns a diverse portfolio of modalities for oncology, including bispecific antibodies, antibody-drug conjugates, and mRNA cancer vaccines, which gives it freedom to explore these in combination for possible synergies.
BioNTech's technology is still relatively new, with no oncology approvals to establish use in this setting.
|
Metric
|
BNTX
|
MRK
|
MRNA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 42.36 | — |
Price/Book Value | 1.13 | 8.00 | 3.80 |
Price/Sales | 7.35 | 5.07 | 11.48 |
Price/Cash Flow | — | 15.22 | — |
|
Metric
|
BNTX
|
MRK
|
MRNA
|
|---|---|---|---|
Quick Ratio | 7.71 | 0.71 | 2.08 |
Current Ratio | 7.85 | 1.32 | 2.29 |
Interest Coverage | — | 4.28 | −79.21 |
|
Metric
|
BNTX
|
MRK
|
MRNA
|
|---|---|---|---|
Return on Assets (Normalized) | −5.73% | 6.27% | −23.64% |
Return on Equity (Normalized) | −6.58% | 16.68% | −33.54% |
Return on Invested Capital (Normalized) | −6.97% | 9.82% | −31.72% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|jRfPS# | LOCK|%^KMk | $131B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|fgj!$DL | LOCK|NNd?Q | $83B | |||
| argenx SE ADR
ARGX
| LOCK|WHC%vtg | LOCK|^^s | $62B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|c%L^Lw!D | LOCK|#$?% | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#%$tNqk | LOCK|D&R | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|p?gSYQj | LOCK|$#Fm< | $30B | |||
| Moderna Inc
MRNA
| LOCK|Z%Y?y#! | LOCK|!&$ | $26B | |||
| Incyte Corp
INCY
| LOCK|%#y&kS | LOCK|nKy | $25B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|ck&gL!H | LOCK|b&^ | $16B |
United States